Subcutaneous Ocrelizumab Not Inferior to IV Infusion
MILAN — An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed. During the first 12 weeks of treatment, blood levels of ocrelizumab — measured as the area under the serum concentration time curve (AUC) […]
No Excess Pregnancy, Infant Risks With Ocrelizumab for MS
Women with multiple sclerosis (MS) who were treated with ocrelizumab (Ocrevus) had no increased risk of adverse pregnancy and infant outcomes, prospective data showed. Cumulative data did not suggest an increased risk of preterm birth, major congenital anomalies, or other adverse outcomes with ocrelizumab in utero exposure and were consistent with epidemiological data, reported Celia […]